To examine the benefits and risks of long-term anticoagulation (warfarin) compared with antiplatelet treatment (aspirin, indobufen) in patients with non-rheumatic atrial fibrillation.
follow-up, international normalised ratio (INR), method of random allocation, blinding used, withdrawals, number in each arm of the study, incidence of fatal outcomes (stroke, vascular, all-cause) and nonfatal outcomes (stroke, TIA, thromboembolism, MI) and other outcomes (combined fatal and non-fatal, trial-defined primary outcome and major bleeds).
Methods of synthesis
How were the studies combined? A meta-analysis was performed using the fixed-effect model to pool the results across studies. Analysis was confined to intention to treat principles, in which all patients randomised were included. Where heterogeneity was found significant with the fixed-effect model, the random-effects model was used. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate treatment effects. STATA was used to assess funnel plot asymmetry, on order to investigate publication bias.
How were differences between studies investigated?
The authors state that pooled effect estimates and heterogeneity between studies were tested using a statistical package (REVMAN 3.1).
Results of the review
Five RCTs (n=3,298) were included.
Five trials were identified. One trial used age-stratified randomisation but since the duration of follow-up was longer for patients in the younger group, this was considered to be two trials for the purposes of the review.
In total, there were 82 fatal vascular events in the anticoagulation group and 95 in the antiplatelet group. Two trials were stopped prematurely, the first because of the significant treatment effect favouring warfarin, when only half of the planned numbers had been recruited, and the second because another trial indicated that low-intensity warfarin plus aspirin was significantly less effective than adjusted warfarin.
The pooled OR from the fixed-effect model showed non significant trends in favour of anticoagulation in deaths from stroke (OR 0.74, 95% CI: 0.39, 1.40), and vascular death (OR 0.86, 95% CI: 0.63, 1.17). Pooled ORs for other outcomes were: all-cause mortality, 0.94 (95% CI: 0.72, 1.21); nonfatal stroke, 0.68 (95% CI: 0.46, 0.99); nonfatal MI, 0.83 (95% CI: 0.46, 1.50); trial-defined primary outcome, 0.73 (95% CI: 0.52, 1.02). There were more major bleeding events in the anticoagulation group than the antiplatelet group (OR 1.45, 95% CI: 0.93, 2.27). Using the random-effects model, because of heterogeneity between trials, the OR for combined fatal and nonfatal events was 0.79 (95% CI: 0.61, 1.02).
A sensitivity analysis, excluding one trial that was considered methodologically weaker than the others, showed a reduction in heterogeneity between trials and attenuated non significant effects of anticoagulation, compared with antiplatelet treatment, in nonfatal stroke (OR 0.75, 95% CI: 0.50, 1.13) and combined fatal and nonfatal outcomes (OR 0.84, 95% CI: 0.67, 1.06).
In 4 of the 5 trials, the INRs were higher than the recommended range of 2 to 3 although all trials stated that anticoagulant control was adequate.
No evidence of publication bias was found. Meta-regression on quality of outcome in trials showed no significant trend.
